Vnitr Lek 2011, 57(10):858-866

Diagnostika a léčba komunitní pneumonie dospělých

V. Kolek*, M. Kolář, V. Kašák, J. Beneš, J. Dindoš
Česká pneumologická a ftizeologická společnost České lékařské společnosti J. E. Purkyně, Společnost infekčního lékařství České lékařské společnosti J. E. Purkyně

Received: March 21, 2011; Published: October 1, 2011  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kolek V, Kolář M, Kašák V, Beneš J, Dindoš J. Diagnostika a léčba komunitní pneumonie dospělých. Vnitr Lek. 2011;57(10):858-866.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Kolek V. Pneumonie - diagnostika a léčba. Praha: Triton 2003.
    2. Niederman MS, McCombs JS, Unger AN et al. The cost of treating community-acquired pneumonia. Clin Ther 1998; 20: 820-837. Go to original source... Go to PubMed...
    3. Guest JF, Morris A. Community-acquired pneumonia: the annual cost to the National Health Service in the United Kingdom. Eur Respir J 1997; 10: 1530-1534. Go to original source... Go to PubMed...
    4. Loddenkemper R. European Lung WhiteBook. Charlesworth Gr.: Huddersfield 2004.
    5. File TM. Community-acquired pneumonia. Lancet 2003; 362: 1991-2001. Go to original source... Go to PubMed...
    6. Barlow GD, Lamping DL, Davey PG et al. Evaluation of outcomes in community-acquired pneumonia: a guide for patients, physicians, and policy-makers. Lancet Infect Dis 2003; 3: 476-488. Go to original source... Go to PubMed...
    7. Woodhead M, Blasi F, Ewig S et al. European Respiratory Society; European Society of Clinical Microbiology and Infectious Diseases. Guidelines for management of adult lower respiratory trect infections. Eur Respir J 2005; 26: 1138-1180. Go to original source... Go to PubMed...
    8. Mandell LA, Bartlett JG, Dowell FS et al. Infectious Diseases Society of America. Update of practice quidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis 2003; 37: 1405-1433. Go to original source... Go to PubMed...
    9. Macfarlane JT, Boldy D. 2004 update of BTS pneumonia guidelines: What's new? Thorax 2004; 59: 364-366. Go to original source... Go to PubMed...
    10. Kolek V. Standard diagnostiky a léčby komunitně získané pneumonie dospělých. Bulletin ČPFS 1995; 5: 9-12.
    11. Dean NC, Silver MP, Bateman KA et al. Decreased mortality after implementation of a treatment guideline for community-acquired pneumonia. Am J Med 2001; 110: 451-457. Go to original source... Go to PubMed...
    12. Martinez JA, Horcajada JP, Almela M et al. Addition of a macrolide to a β-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteraemic pneumococcal pneumonia. Clin Infect Dis 2003; 36: 385-395. Go to original source... Go to PubMed...
    13. Gleason PP, Meehan TP, Fine JM et al. Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia. Arch Int Med 1999; 159: 2561-2572. Go to original source... Go to PubMed...
    14. Kolek V, Fila L, Fojtů H et al. Pneumonie vyžadující hospitalizaci: výsledky dvouleté multicentrické studie v České republice. Int Med Prax 2003; 7: 347-352.
    15. de Roux A, Ewig S, García E et al. Mixed community-acquired pneumonia in hospitalised patients. Eur Respir J 2006; 27: 795-800. Go to original source... Go to PubMed...
    16. File TM Jr, Plouffe JF Jr, Breiman RF et al. Clinical Characteristics of Chlamydia pneumoniae infection as the sole cause of community-Acquired Pneumonia. Clin Infect Dis 1999; 29: 426-428. Go to original source... Go to PubMed...
    17. File TM Jr, Tan JS. International guidelines for the treatment of community - acquired pneumonia in adults. The role of macrolides. Drugs 2003; 63: 181-205. Go to original source... Go to PubMed...
    18. Koivula I, Stén M, Mäkelä PH. Prognosis after community-acquired pneumonia in the elderly: a population-based 12 year follow-up study. Arch Int Med 1999; 159: 1550-1555. Go to original source... Go to PubMed...
    19. Metlay JP, Atlas SJ, Borowsky LH et al. Time course of symptom resolution in patients with community-acquired pneumonia. Respir Med 1998; 92: 1137-1142. Go to original source... Go to PubMed...
    20. Halm EA, Fine MJ, Kapoor WN et al. Instability on hospital discharge and the risk of adverse outcomes in patients with pneumonia. Arch Intern Med 2002; 162: 1278-1284. Go to original source... Go to PubMed...
    21. Fine MJ, Smith MA, Carson CA et al. Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis. JAMA 1996; 275: 134-141. Go to original source...
    22. Lim WS, van der Eerden MM, Laing R et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003; 58: 377-382. Go to original source... Go to PubMed...
    23. Rhew DC, Tu GS, Ofman J et al. Early switch and early discharge strategies in patients with community-acquired pneumonia: a meta-analysis. Arch Intern Med 2001; 161: 722-727. Go to original source... Go to PubMed...
    24. Waterer GW, Somes GW, Wunderink RG. Monotherapy may be suboptimal for severe bacteraemic pneumococcal pneumonia. Arch Intern Med 2001; 161: 1837-1842. Go to original source... Go to PubMed...
    25. Ewig S, Ruiz M, Torres A et al. Pneumonia acquired in the community through drug-resistant Streptococcus pneumoniae. Am J Respir Crit Care Med 1999; 159: 1835-1842. Go to original source... Go to PubMed...
    26. Ho PL, Tse WS, Tsang KW et al. Risk factors for acquisition of levofloxacin-resistant Streptococcus pneumoniae: A case-control study. Clin Inf Dis 2001; 32: 701-707. Go to original source... Go to PubMed...
    27. Kolář M, Urbánek K, Čekanová L. Podklady pro racionální antibiotickou léčbu komunitních bakteriálních infekcí. Klin Farmakol Farmac 2003; 17: 22-24.
    28. Kolář M. Komunitní pneumonie z pohledu mikrobiologa. Stud Pneumol Phthiseol 2003; 63: 164-167.
    29. Capelastequi A, España PP, Quintana JM et al. Validation of a predictive rule for the management of community-acquired pneumonia. Eur Respir J 2006; 27: 151-157. Go to original source... Go to PubMed...
    30. Mandell LA, Wunderink RG, Anzueto A et al. Infectious Diseases Society of America. American Thoracic Society. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44 (Suppl 2): S27-S72. Go to original source... Go to PubMed...
    31. Kolek V, Kašák V, Skřičková J et al. Pneumologie: Vybrané kapitoly pro praxi. Praha: Maxdorf Jessenius 2010.
    32. Woodhead M, Blasi F, Ewig S et al. European Society of Clinical Microbiology and Infectious Diseases. Guidelines for management of adult lower respiratory tract infections. Eur Respir J 2005; 26: 1138-1180. Go to original source... Go to PubMed...
    33. Bukghardt O, Welte T. 10 years' experience with pneumococcal quinolone moxifloxacin. Expert Rev Anti Infect Ther 2009; 7: 645-668. Go to original source... Go to PubMed...
    34. Torres A, Muir JF, Corris P et al. Effectiveness of oral moxifloxacin in standard first-line therapy in community-acquired pneumonia. Eur Respir J 2003; 21: 135-143. Go to original source... Go to PubMed...
    35. Welte T, Petermann W, Schürmann D et al. MOXIRAPID Study Group. Treatment with sequential intravenous or oral moxifloxacin was associated with faster clinical improvement than was standard therapy for hospitalized patients with community-acquired pneumonia who received initial parenteral therapy. Clin Infect Dis 2005; 41: 1697-1705. Go to original source... Go to PubMed...
    36. Torres A, Garau J, Arvis P et al. MOTIV (MOxifloxacin Treatment IV) Study Group. Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: The MOTIV Study - a randomized clinical trial. Clin Infect Dis 2008; 46: 1499-1509. Go to original source... Go to PubMed...
    37. Jakubec P, Kolek V, Kolář M. Klinické doporučení diagnostiky a léčby těžké pneumonie. Praha: Dashofer 2009.
    38. Kolek V, Kolář M, Kašák V et al. Klinické doporučení diagnostika a léčby komunitní pneumonie dospělých. Praha: Dashofer 2006.
    39. Beneš J, Bartošová D, Beran J et al. Infekční lékařství. Praha: Galén 2009.

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.